These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26250457)

  • 1. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
    Sun L; Guo H; Jiang R; Lu L; Liu T; He X
    Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of PLGA nanoparticles conjugated with anti-OX40/anti-AFP mAbs on cytotoxicity of CTL cells against hepatocellular carcinoma].
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Apr; 30(4):337-41. PubMed ID: 24721396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
    Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.
    Liu Y; Butterfield LH; Fu X; Song Z; Zhang X; Lu C; Ding G; Wu M
    Int J Oncol; 2011 Jul; 39(1):245-53. PubMed ID: 21491085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
    Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
    Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
    Hussein MS; Li Q; Mao R; Peng Y; He Y
    Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
    Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
    Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Studies of the Off-Target Reactivity of AFP
    Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
    Front Immunol; 2020; 11():607. PubMed ID: 32395117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental and clinical research of cytolytic T lymphocytes specific for hepatocellular carcinoma].
    Shen F; Wang H; Xie T
    Zhonghua Wai Ke Za Zhi; 1997 Feb; 35(2):95-9. PubMed ID: 10374486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
    Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
    Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.
    Kumar J; Kale V; Limaye L
    Stem Cell Res Ther; 2015 Sep; 6():184. PubMed ID: 26407613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
    Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
    Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.